Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6062927 | 0.83 | REN (0.37) | RENCYP1A2CYP2C19 | |
| SCHEMBL6062924 | 0.83 | REN (0.37) | RENCYP1A2CYP2C19 | |
| SCHEMBL6062920 | 0.83 | REN (0.37) | RENCYP1A2CYP2C19 | |
| SCHEMBL6630597 | 0.76 | CTSS (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL6630590 | 0.76 | CTSS (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL6630594 | 0.76 | CTSS (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL6630981 | 0.75 | CTSS (0.34) | CYP3A4CYP2C9 | |
| SCHEMBL6630976 | 0.75 | CTSS (0.34) | CYP3A4CYP2C9 | |
| SCHEMBL6630977 | 0.75 | CTSS (0.34) | CYP3A4CYP2C9 | |
| SCHEMBL6692449 | 0.72 | CTSC (0.48) | CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | TP53 319/4885HTT 1566/4885TSHR 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.